Stocksigma LogoStocksigma Logo

Molbio Diagnostics Q1 FY27 Performance Update

Molbio Diagnostics reported Q1 FY27 total income of ₹411.5 Cr, up from ₹100.5 Cr in Q1 FY26, boosted by ~₹57 Cr of deferred Q4 FY26 export orders

Molbio Diagnostics Q1 FY27 Performance Update

Molbio Diagnostics Ltd · Investor Presentation · 08 Sept 2026, 8:27 pm

Molbio Diagnostics Q1 FY27 Performance Update Molbio Diagnostics reported Q1 FY27 total income of ₹411.5 Cr, up from ₹100.5 Cr in Q1 FY26, boosted by ~₹57 Cr of deferred Q4 FY26 export orders. EBITDA turned around to ₹103.7 Cr (25.2% margin) versus a loss of ₹14.5 Cr in Q1 FY26, while PAT reached ₹52.7 Cr against a net loss of ₹23.9 Cr. Growth was driven by Truenat test kit volumes reaching 6.2 Mn units. Capacity utilization stood at 58.25% for test kits and 42.30% for devices in FY26.

Original exchange filing (PDF)

More announcements from Molbio Diagnostics Ltd

All Molbio Diagnostics Ltd announcements